Allakos Inc. (NASDAQ:ALLK), a clinical-stage biopharmaceutical company developing therapeutic monoclonal antibodies for treatment of inflammatory, and proliferative diseases, faced a setback with disappointing results from a crucial phase 3 trial named Enigma 2 and phase 2/3 Kryptos trial. 

Should you invest in the Company or watch from the sidelines? 

Read on to find out more!